

SUBSTITUTE FOR FORM IPC/SB/08			ATTY DOCKET NO: LONGENECKER=7A		SERIAL NO: 10/594,992	
INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT			FIRST INVENTOR: LONGENECKER, Michael B.			
			FILING DATE: November 16, 2006			
			EXAMINER: FETTEROLF, B.		ART UNIT: 1642	
U.S. PATENT DOCUMENTS (include at least patentee, patent/pub number and filing/issue/pub date)						
EXAM. INITIAL	ID	DOCUMENT NUMBER	FILING, ISSUE OR PUBLICATION DATE MM-DD-YYYY	PATENTEE OR APPLICANT	Relevant Passage(s)	T*
FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)						
EXAM. INITIAL	ID	COUNTRY CODE & DOCUMENT NUMBER	PUBLICATION DATE MM-DD-YYYY	PATENTEE OR APPLICANT	Relevant Passage(s)	T*
OTHER DOCUMENTS (include AUTHOR, title, name of publication, volume, pages & date of publication) Please list in alphabetical order.						
BF	BA	MORSE, Michael A., "Technology Evaluation: BLP-25, Biomira Inc", <u>CURRENT OPINION IN MOLECULAR THERAPEUTICS</u> , vol. 3, no. 1, pp. 102-105, 2001.				
BF	BB	PANTUCK, et al., "Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-Positive Patients with Advanced Prostate Cancer", <u>J. IMMUNOTHER.</u> , vol. 27, no. 3, pp. 240-253, May/June 2004.				
BF	BC	SCHUT, et al., "MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue", <u>BJU INTERNATIONAL</u> , vol. 91, no. 3, pp. 278-283, February 2003.				
EXAMINER			/Brandon J. Fetterolf/		DATE CONSIDERED 6/18/2009	
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.						

* "Relevant Passages" column is optional. Put check in "T" column if English translation of entire document included. If English language abstract included, put A in this box. If ref. in English, put "E". If requirement otherwise met, put O.